Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estrategia de DAPT en Pacientes HBR Sometidos a ICP Compleja Tras un SCA: Segunda Fase de Pruebas Beta de una Ayuda para la Decisión del Paciente (BETA-DAPT)

8 de noviembre de 2026 actualizado por: Julien Quang Le Van, Montreal Heart Institute

Estrategia de Terapia Antiplaquetaria Dual en Pacientes con Alto Riesgo Hemorrágico Sometidos a Intervención Coronaria Percutánea Compleja tras un Síndrome Coronario Agudo: Segunda Fase de Pruebas Beta de una Ayuda para la Decisión del Paciente

Among patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI) and stent implantation, 17.5% are both at high bleeding risk (HBR) and have undergone complex PCI, which also places them at high thrombotic risk. In this population, several dual antiplatelet therapy (DAPT) strategies may be considered: (1) de-escalation of DAPT intensity after 1 to 3 months (switch from ticagrelor/prasugrel to clopidogrel), (2) shortening DAPT duration to 1 to 3 months followed by antiplatelet monotherapy, (3) 12-month clopidogrel-based DAPT, and (4) 12-month ticagrelor/prasugrel-based DAPT. Selecting the most appropriate DAPT strategy in this dual-risk context is complex, and clinical trial evidence is limited for this specific subgroup. In the absence of clear guideline recommendations to support decision-making for patients facing both elevated bleeding and thrombotic risks, structured shared decision-making support is needed.

In this context, within research project 2025-3499 conducted with pharmacy residents, we developed a patient decision aid (PDA) designed to support shared decision-making by helping patients understand their risks, available options, and potential consequences, so they can express their preferences regarding antiplatelet therapy. The PDA aims to facilitate shared decisions by improving patients' understanding of benefits and harms and aligning choices with patient values. A preliminary version of the tool has already undergone alpha testing with a small group of internal users (physicians, pharmacists, and patient partners). The next step is beta testing, that is, real-world testing with the target population and clinicians to evaluate usability and acceptability in routine practice.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Actual)

10

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Quebec
      • Montreal, Quebec, Canadá, H1T 1C8
        • Montreal Heart Institute

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria (Patients)

  • Adults aged 18 years or older
  • Hospitalized on the coronary care unit ward at the Montreal Heart Institute (MHI)
  • Acute coronary syndrome (ACS) during the current episode of care, treated with PCI and placement of one or more coronary stents
  • High bleeding risk based on PRECISE-HBR score and high thrombotic risk, with both risks considered of comparable clinical importance by the treating medical team

Inclusion Criteria (Clinicians)

- Clinicians working in the MHI coronary care unit (cardiologists, medical residents, nurse practitioners, or pharmacists) who use the patient decision aid with one or more study participants

Exclusion Criteria (Patients)

  • Receiving therapeutic anticoagulation
  • Planned cardiac surgery during the same episode of care
  • Prior history of coronary stent thrombosis
  • Antiphospholipid syndrome or known thrombophilia
  • Unable to participate in shared decision-making
  • Unable to understand spoken and written French or English
  • Concurrent participation in another study (followed within another research protocol)
  • Transferred from another center for reasons other than coronary angiography at MHI and expected to return to the referring center for ongoing care (i.e., "fly-in/fly-out" patients)

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Otro
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Otro: High bleeding risk patients treated with complex PCI in the context of ACS

The intervention is the use of the Patient Decision Aid (PDA) to support shared decision-making between patients and clinicians after PCI, assessed using questionnaires capturing multiple dimensions of decision quality.

No pharmacologic treatment is administered as part of the study; exposure consists solely of complete use of the PDA according to the protocol.

The study includes a single pre-post group, no interim analyses are planned given the limited project duration, and a single beta-testing phase will be conducted.

Patient decision aid to support shared decision-making between patients and clinicians by helping patients understand their risks, available options, and potential consequences, so they can express their preferences regarding antiplatelet therapy.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Decisional Conflict (DCS-LL) After Use of the Patient Decision Aid (PDA)
Periodo de tiempo: Baseline (pre-PDA, Day 0) and immediately post-PDA completion (Day 0, index hospitalization).

Change in total score on the low-literacy Decisional Conflict Scale (DCS-LL; Ottawa Hospital Research Institute), comparing pre-PDA vs post-PDA completion. Lower scores indicate less decisional conflict.

Baseline (pre-PDA, Day 0) and immediately post-PDA completion (Day 0, index hospitalization).

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Antiplatelet Strategy Knowledge Score After PDA Use
Periodo de tiempo: Baseline (pre-PDA, Day 0) and immediately post-PDA completion (Day 0, index hospitalization).

Change in total score on an adapted OHRI knowledge questionnaire assessing understanding of bleeding and thrombotic risks and DAPT options, comparing pre-PDA vs post-PDA completion.

Baseline (pre-PDA, Day 0) and immediately post-PDA completion (Day 0, index hospitalization).
Preparation for Decision-Making (PrepDM) Score After PDA Use
Periodo de tiempo: Immediately post-PDA completion (Day 0, index hospitalization).

Total score on the Preparation for Decision Making (PrepDM; OHRI) questionnaire completed after PDA use. Higher scores indicate greater perceived preparedness to make a decision with the clinician.

Immediately post-PDA completion (Day 0, index hospitalization).
Patient Acceptability Score of the PDA in Routine Clinical Use
Periodo de tiempo: Immediately post-PDA completion (Day 0, index hospitalization).

Total score on an OHRI acceptability questionnaire completed after PDA use, reflecting perceived relevance, clarity, length, and overall acceptability in the clinical setting.

Immediately post-PDA completion (Day 0, index hospitalization).
Patient Refusal Rate to Use the PDA and Reasons for Refusal
Periodo de tiempo: Pre-intervention (at the time of the consent request, prior to PDA delivery, during the index hospitalization).

Number and proportion of eligible patients who personally refuse participation/PDA use, and categorization of documented reasons for refusal (e.g., not interested, too tired, overwhelmed, language barriers, time constraints).

Pre-intervention (at the time of the consent request, prior to PDA delivery, during the index hospitalization).
Agreement Between Patient-Preferred Antiplatelet Strategy and Strategy Prescribed at Hospital Discharge
Periodo de tiempo: At hospital discharge (index hospitalization), comparing the patient preference recorded immediately after PDA completion with the antiplatelet strategy on the discharge prescription/orders (also post-PDA completion).

Proportion of agreement between (a) the antiplatelet strategy preferred by the patient as identified through the PDA and (b) the antiplatelet strategy documented on the discharge prescription/orders.

At hospital discharge (index hospitalization), comparing the patient preference recorded immediately after PDA completion with the antiplatelet strategy on the discharge prescription/orders (also post-PDA completion).
Clinician Usability of the PDA (French System Usability Scale, F-SUS)
Periodo de tiempo: Day 0 (immediately after PDA use with an included patient)

Total score on the French System Usability Scale (F-SUS) completed by clinicians after using the PDA with an included patient in routine clinical care. Higher scores indicate better usability.

Day 0 (immediately after PDA use with an included patient)
Clinician Refusal Rate to Use the PDA and Reasons for Non-Use
Periodo de tiempo: Pre-intervention (at the time the clinician is asked whether it is appropriate to approach the patient and offer the PDA, prior to patient approach and prior to PDA delivery, during the index hospitalization).

Number and proportion of eligible patient encounters in which the clinician declines to use the PDA when asked, along with categorization of documented reasons (e.g., time constraints, clinical instability, workflow barriers, clinician preference).

Pre-intervention (at the time the clinician is asked whether it is appropriate to approach the patient and offer the PDA, prior to patient approach and prior to PDA delivery, during the index hospitalization).

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Exploratory Subgroup Effects on Decisional Conflict Scores Low Litteracy (DCS-LL) Questionnaire
Periodo de tiempo: Baseline (pre-PDA, Day 0) and immediately post-PDA completion (Day 0, index hospitalization).

Exploratory assessment of whether changes in DCS-LL differ by prespecified characteristics: age (<70 vs ≥70 years), sex (male vs female), mother tongue (French vs English), education level (university vs lower) and prior percutaneous intervention with stent (yes or no). Analyses are descriptive/exploratory.

Baseline (pre-PDA, Day 0) and immediately post-PDA completion (Day 0, index hospitalization).

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de febrero de 2026

Finalización primaria (Actual)

30 de septiembre de 2026

Finalización del estudio (Actual)

30 de septiembre de 2026

Fechas de registro del estudio

Enviado por primera vez

8 de enero de 2026

Primero enviado que cumplió con los criterios de control de calidad

29 de enero de 2026

Publicado por primera vez (Actual)

5 de febrero de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

8 de noviembre de 2026

Última verificación

1 de enero de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir